drugset
drugset / Trial / NCT00268723

Efficacy Study of Single-Dose Levalbuterol Tartrate HFA MDI Vs Placebo in Subjects 18 Years and Older With EIB

NCT00268723 ↗

Phase 3 Completed 15 enrolled Sumitomo Pharma America, Inc.
RandomizedCrossoverTriple-blindTreatment

Summary

To determine if administration of levalbuterol tartrate HFA MDI in subjects with EIB will be effective in the prevention of EIB and be safe and well-tolerated.

Timeline

Start
2005-12
Primary completion
2006-02
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Levalbuterol Other / unclassified 90 ug Inhaled

Indications

exercise-induced bronchoconstriction